|
1
|
Graham SM, Jørgensen HG, Allan E, Pearson
C, Alcorn MJ, Richmond L and Holyoake TL: Primitive, quiescent,
Philadelphia-positive stem cells from patients with chronic myeloid
leukemia are insensitive to STI571 in vitro. Blood. 99:319–325.
2002. View Article : Google Scholar
|
|
2
|
Mahon FX, Réa D, Guilhot J, Guilhot F,
Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B,
et al Intergroupe Français des Leucémies Myéloïdes Chroniques:
Discontinuation of imatinib in patients with chronic myeloid
leukaemia who have maintained complete molecular remission for at
least 2 years: The prospective, multicentre Stop Imatinib (STIM)
trial. Lancet Oncol. 11:1029–1035. 2010. View Article : Google Scholar
|
|
3
|
Corbin AS, Agarwal A, Loriaux M, Cortes J,
Deininger MW and Druker BJ: Human chronic myeloid leukemia stem
cells are insensitive to imatinib despite inhibition of BCR-ABL
activity. J Clin Invest. 121:396–409. 2011. View Article : Google Scholar
|
|
4
|
Abraham SA, Hopcroft LE, Carrick E, Drotar
ME, Dunn K, Williamson AJ, Korfi K, Baquero P, Park LE, Scott MT,
et al: Dual targeting of p53 and c-MYC selectively eliminates
leukaemic stem cells. Nature. 534:341–346. 2016. View Article : Google Scholar
|
|
5
|
Collins SJ, Bodner A, Ting R and Gallo RC:
Induction of morphological and functional differentiation of human
promyelocytic leukemia cells (HL-60) by componuds which induce
differentiation of murine leukemia cells. Int J Cancer. 25:213–218.
1980. View Article : Google Scholar
|
|
6
|
Honma Y: Cotylenin A - a plant growth
regulator as a differentiation-inducing agent against myeloid
leukemia. Leuk Lymphoma. 43:1169–1178. 2002. View Article : Google Scholar
|
|
7
|
Ishii Y, Kasukabe T and Honma Y: Immediate
up-regulation of the calcium-binding protein S100P and its
involvement in the cytokinin-induced differentiation of human
myeloid leukemia cells. Biochim Biophys Acta. 1745:156–165. 2005.
View Article : Google Scholar
|
|
8
|
Ishii Y, Kasukabe T and Honma Y: Induction
of CCAAT/enhancer binding protein-delta by cytokinins, but not by
retinoic acid, during granulocytic differentiation of human myeloid
leukaemia cells. Br J Haematol. 128:540–547. 2005. View Article : Google Scholar
|
|
9
|
Tsumura H, Akimoto M, Kiyota H, Ishii Y,
Ishikura H and Honma Y: Gene expression profiles in differentiating
leukemia cells induced by methyl jasmonate are similar to those of
cytokinins and methyl jasmonate analogs induce the differentiation
of human leukemia cells in primary culture. Leukemia. 23:753–760.
2009. View Article : Google Scholar
|
|
10
|
Liebermann DA and Hoffman B:
Differentiation primary response genes and proto-oncogenes as
positive and negative regulators of terminal hematopoietic cell
differentiation. Stem Cells. 12:352–369. 1994. View Article : Google Scholar
|
|
11
|
Dimberg A, Bahram F, Karlberg I, Larsson
LG, Nilsson K and Oberg F: Retinoic acid-induced cell cycle arrest
of human myeloid cell lines is associated with sequential
down-regulation of c-Myc and cyclin E and post-transcriptional
up-regulation of p27(Kip1). Blood. 99:2199–2206. 2002. View Article : Google Scholar
|
|
12
|
Hu XT and Zuckerman KS: Role of cell cycle
regulatory molecules in retinoic acid- and vitamin D3-induced
differentiation of acute myeloid leukaemia cells. Cell Prolif.
47:200–210. 2014. View Article : Google Scholar
|
|
13
|
Yamada K, Honma Y, Asahi KI, Sassa T, Hino
KI and Tomoyasu S: Differentiation of human acute myeloid leukaemia
cells in primary culture in response to cotylenin A, a plant growth
regulator. Br J Haematol. 114:814–821. 2001. View Article : Google Scholar
|
|
14
|
Honma Y, Ishii Y, Sassa T and Asahi K:
Treatment of human promyelocytic leukemia in the SCID mouse model
with cotylenin A, an inducer of myelomonocytic differentiation of
leukemia cells. Leuk Res. 27:1019–1025. 2003. View Article : Google Scholar
|
|
15
|
Lozzio BB and Lozzio CB: Properties of the
K562 cell line derived from a patient with chronic myeloid
leukemia. Int J Cancer. 19:1361977. View Article : Google Scholar
|
|
16
|
Kishi K: A new leukemia cell line with
Philadelphia chromosome characterized as basophil precursors. Leuk
Res. 9:381–390. 1985. View Article : Google Scholar
|
|
17
|
Maniwa Y, Kasukabe T and Kumakura S:
Vitamin K2 and cotylenin A synergistically induce monocytic
differentiation and growth arrest along with the suppression of
c-MYC expression and induction of cyclin G2 expression in human
leukemia HL-60 cells. Int J Oncol. 47:473–480. 2015. View Article : Google Scholar
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
19
|
Terstappen LW, Huang S, Safford M,
Lansdorp PM and Loken MR: Sequential generations of hematopoietic
colonies derived from single nonlineage-committed
CD34+CD38− progenitor cells. Blood.
77:1218–1227. 1991.
|
|
20
|
Wang Z, Liu Z, Wu X, Chu S, Wang J, Yuan
H, Roth M, Yuan YC, Bhatia R and Chen W: ATRA-induced cellular
differentiation and CD38 expression inhibits acquisition of BCR-ABL
mutations for CML acquired resistance. PLoS Genet. 10:e10044142014.
View Article : Google Scholar
|
|
21
|
Takahashi T, Honma Y, Miyake T, Adachi K,
Takami S, Okada M, Kumanomidou S, Ikejiri F, Jo Y, Onishi C, et al:
Synergistic combination therapy with cotylenin A and vincristine in
multiple myeloma models. Int J Oncol. 46:1801–1809. 2015.
View Article : Google Scholar
|
|
22
|
Kawakami K, Hattori M, Inoue T, Maruyama
Y, Ohkanda J, Kato N, Tongu M, Yamada T, Akimoto M, Takenaga K, et
al: A novel fusicoccin derivative preferentially targets hypoxic
tumor cells and inhibits tumor growth in xenografts. Anticancer
Agents Med Chem. 12:791–800. 2012. View Article : Google Scholar
|
|
23
|
Miyake T, Honma Y, Urano T, Kato N and
Suzumiya J: Combined treatment with tamoxifen and a fusicoccin
derivative (ISIR-042) to overcome resistance to therapy and to
enhance the antitumor activity of 5-fluorouracil and gemcitabine in
pancreatic cancer cells. Int J Oncol. 47:315–324. 2015. View Article : Google Scholar
|
|
24
|
Honma Y, Ishii Y, Yamamoto-Yamaguchi Y,
Sassa T and Asahi K: Cotylenin A, a differentiation-inducing agent,
and IFN-alpha cooperatively induce apoptosis and have an antitumor
effect on human non-small cell lung carcinoma cells in nude mice.
Cancer Res. 63:3659–3666. 2003.
|
|
25
|
Oecking C, Eckerskorn C and Weiler EW: The
fusicoccin receptor of plants is a member of the 14-3-3 superfamily
of eukaryotic regulatory proteins. FEBS Lett. 352:163–166. 1994.
View Article : Google Scholar
|
|
26
|
Rittinger K, Budman J, Xu J, Volinia S,
Cantley LC, Smerdon SJ, Gamblin SJ and Yaffe MB: Structural
analysis of 14-3-3 phosphopeptide complexes identifies a dual role
for the nuclear export signal of 14-3-3 in ligand binding. Mol
Cell. 4:153–166. 1999. View Article : Google Scholar
|
|
27
|
Fujita N, Sato S and Tsuruo T:
Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal
protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic
localization. J Biol Chem. 278:49254–49260. 2003. View Article : Google Scholar
|
|
28
|
el-Deiry WS, Tokino T, Velculescu VE, Levy
DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and
Vogelstein B: WAF1, a potential mediator of p53 tumor suppression.
Cell. 75:817–825. 1993. View Article : Google Scholar
|
|
29
|
Moslehi JJ and Deininger M: Tyrosine
kinase inhibitor-associated cardiovascular toxicity in chronic
myeloid leukemia. J Clin Oncol. 33:4210–4218. 2015. View Article : Google Scholar
|
|
30
|
Caldemeyer L, Dugan M, Edwards J and Akard
L: Long-term side effects of tyrosine kinase inhibitors in chronic
myeloid leukemia. Curr Hematol Malig Rep. 11:71–79. 2016.
View Article : Google Scholar
|
|
31
|
Ågerstam H, Hansen N, von Palffy S, Sandén
C, Reckzeh K, Karlsson C, Lilljebjörn H, Landberg N, Askmyr M,
Högberg C, et al: IL1RAP antibodies block IL-1-induced expansion of
candidate CML stem cells and mediate cell killing in xenograft
models. Blood. 128:2683–2693. 2016. View Article : Google Scholar
|
|
32
|
Zhang B, Chu S, Agarwal P, Campbell VL,
Hopcroft L, Jørgensen HG, Lin A, Gaal K, Holyoake TL and Bhatia R:
Inhibition of interleukin-1 signaling enhances elimination of
tyrosine kinase inhibitor-treated CML stem cells. Blood.
128:2671–2682. 2016. View Article : Google Scholar
|
|
33
|
Cheloni G, Tanturli M, Tusa I, Ho DeSouza
N, Shan Y, Gozzini A, Mazurier F, Rovida E, Li S and Dello Sbarba
P: Targeting chronic myeloid leukemia stem cells with the
hypoxia-inducible factor inhibitor acriflavine. Blood. 130:655–665.
2017. View Article : Google Scholar
|
|
34
|
Kuntz EM, Baquero P, Michie AM, Dunn K,
Tardito S, Holyoake TL, Helgason GV and Gottlieb E: Targeting
mitochondrial oxidative phosphorylation eradicates
therapy-resistant chronic myeloid leukemia stem cells. Nat Med.
23:1234–1240. 2017. View
Article : Google Scholar
|
